| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Simplifying a complex
medical journey
Advancing patient care with superior testing
As a pioneer in the field, Mayo Clinic plays an integral role by developing new tests to help align patients with new therapies for plasma cell disorders. Our algorithmic approach ensures that the right tests are ordered at the right time, and that health care providers get clinically actionable answers for their patients faster. And testing with Mayo Clinic means 24/7 access to our physician and laboratory experts, who are leaders in their fields.
With you every step of the way
Screening
A groundbreaking method to accurately identify monoclonal proteins and determine risk of progression
Diagnosis and risk stratification
A simplified approach to risk stratification and diagnosis using the Mayo Stratification for Myeloma and Risk-Adapted Therapy (mSMART)
Monitoring
Accurate monitoring of patients to determine response to therapy and risk of relapse
Breaking down the facts
When a patient presents with a monoclonal protein (M-protein) disorder, the answer is not always multiple myeloma. From the more common diagnosis of monoclonal gammopathy of undetermined significance (MGUS), to rarer findings such as amyloid light-chain (AL) amyloidosis or POEMS syndrome, it is becoming more recognized that plasma cell neoplasms are not just one disease, and they are characterized by marked protein, cytogenetic, molecular, and proliferative heterogeneity. Clinicians are increasingly challenged to provide answers in this rapidly changing environment. Advances in testing methodologies, novel therapies, and individualized treatment regimens continually add to the complexity of helping patients. Whether you’re screening, diagnosing, or monitoring patients, we offer leading edge testing while keeping patient care local.
How an ex-NFL linebacker overcame his greatest opponent, amyloidosis
Matt Millen, ex-pro NFL player, who played on four Super Bowl-winning teams underwent a nearly six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic.
Additional resources
The standard laboratory test to diagnose multiple myeloma dates back to the Eisenhower administration. Research at Mayo Clinic spearheaded by David Murray, M.D., Ph.D. (PATH ’10), and fueled by his experience as an industrial chemist has led to a new assay to screen and diagnose the disease.
This "Specialty Testing" webinar will cover the development work, clinical applications, analytical validation, and implementation of a MALDI-TOF mass spectrometry method (MASS-FIX) for the detection of monoclonal immunoglobulins M-proteins within the Mayo Clinic Protein Immunology Laboratory.
Like a thief in the night, multiple myeloma sneaks up on people. The incurable blood cancer almost always starts as a relatively benign condition—monoclonal gammopathy of undetermined significance, or MGUS—that has no symptoms and often goes undiagnosed.
David Murray, M.D., Ph.D., provides an overview of the updated monoclonal gammopathy screening and monitoring tests for multiple myeloma. He discusses when this testing should be ordered, how this approach improves upon previous methods, and what clinical action can be taken from the results of these tests.
Multiple myeloma is the second most common blood cancer, but most people haven’t heard of it until they or someone they know is diagnosed with the disease. March is Myeloma Action Month—a time to focus attention on the fight against multiple myeloma.